Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060

Introduction: Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who received ICI alone (ICI-alone) or with chemotherapy...

Mô tả đầy đủ

Chi tiết về thư mục
Những tác giả chính: Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD
Định dạng: Bài viết
Ngôn ngữ:English
Được phát hành: Elsevier 2024-04-01
Loạt:JTO Clinical and Research Reports
Những chủ đề:
Truy cập trực tuyến:http://www.sciencedirect.com/science/article/pii/S2666364324000250

Những quyển sách tương tự